Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most

References

• Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990-2017. Br J Dermatol. 2021;184(2):1–12. doi: 10.1111/bjd.19580.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract. 2019;7(8):2699–2706.e2697. doi: 10.1016/j.jaip.2019.05.055.
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: 10.1016/S0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• Koszorú K, Borza J, Gulácsi L, et al. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174–177.
   PubMed Web of Science ®Google Scholar
• Hebert AA, Stingl G, Ho LK, et al. Patient impact and economic burden of mild-to-moderate atopic dermatitis. Curr Med Res Opin. 2018;34(12):2177–2185. doi: 10.1080/03007995.2018.1498329.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Halling AS, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155–1162. doi: 10.1016/j.jaci.2022.12.002.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345.
   PubMed Web of Science ®Google Scholar
• Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429–438. doi: 10.1016/j.jaci.2013.07.049.
   PubMed Web of Science ®Google Scholar
• Werfel T, Heratizadeh A, Aberer W, et al. S3-Leitlinie “Atopische Dermatitis” (AWMF-Registernr. 013-027). 2023. Available from: https://register.awmf.org/de/leitlinien/detail/013-027.
   Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi: 10.1111/bjd.19574.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–1091. doi: 10.1056/NEJMoa2206714.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740–748. doi: 10.1093/bjd/ljad022.
   PubMed Web of Science ®Google Scholar
• Singh R, Taylor A, Shah MA, et al. Review of tralokinumab in the treatment of atopic dermatitis. Ann Pharmacother. 2023;57(3):333–340. doi: 10.1177/10600280221105686.
   PubMed Web of Science ®Google Scholar
• Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–147. doi: 10.1016/j.jaad.2020.08.051.
   PubMed Web of Science ®Google Scholar
• Sedeh FB, Henning MAS, Jemec GBE, et al. Comparative efficacy and safety of monoclonal antibodies and janus kinase inhibitors in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Acta Derm Venereol. 2022;102:adv00764. doi: 10.2340/actadv.v102.2075.
   PubMed Web of Science ®Google Scholar
• Stölzl D, Sander N, Heratizadeh A, et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol. 2022;187(6):1022–1024. doi: 10.1111/bjd.21794.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an Open-Label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567–577. doi: 10.1007/s40257-020-00527-x.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888–899. doi: 10.1111/bjd.21867.
   PubMed Web of Science ®Google Scholar
• Huang IH, Chung WH, Wu PC, et al. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260. doi: 10.3389/fimmu.2022.1068260.
   PubMedGoogle Scholar
• Silverberg JI, Hong HC, Calimlim BM, et al. Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. Dermatol Ther. 2023;13(10):2247–2264. doi: 10.1007/s13555-023-01000-3.
   Google Scholar
• Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523–532. doi: 10.1001/jamadermatol.2022.0455.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023.
   PubMed Web of Science ®Google Scholar
• Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. doi: 10.1016/S0140-6736(22)01199-0.
   PubMed Web of Science ®Google Scholar
• Kragstrup TW, Glintborg B, Svensson AL, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1):e002236. doi: 10.1136/rmdopen-2022-002236.
   PubMed Web of Science ®Google Scholar
• Samuel C, Cornman H, Kambala A, et al. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther. 2023;13(3):729–749. doi: 10.1007/s13555-023-00892-5.
   Web of Science ®Google Scholar
• David E, Ungar B, Renert-Yuval Y, et al. The evolving landscape of biologic therapies for atopic dermatitis: present and future perspective. Clin Exp Allergy. 2023;53(2):156–172. doi: 10.1111/cea.14263.
   PubMed Web of Science ®Google Scholar
• Tsuji G, Yamamura K, Kawamura K, et al. Novel therapeutic targets for the treatment of atopic dermatitis. Biomedicines. 2023;11(5):1303. doi: 10.3390/biomedicines11051303.
   PubMed Web of Science ®Google Scholar
• Traidl S, Heratizadeh A. Modern systemic therapies for atopic dermatitis: which factors determine the choice of therapy? Dermatologie. 2022;73(7):529–537. doi: 10.1007/s00105-022-05003-7.
   Google Scholar
• Kromer C, Schaarschmidt ML, Schmieder A, et al. Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PLoS One. 2015;10(6):e0129120. doi: 10.1371/journal.pone.0129120.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Herr R, Gutknecht M, et al. Patients’ and physicians’ preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare). Acta Derm Venereol. 2018;98(2):200–205. doi: 10.2340/00015555-2834.
   PubMed Web of Science ®Google Scholar
• Faverio K, Peitsch WK, Görig T, et al. Patient preferences in hidradenitis suppurativa (APProach-HS): a discrete choice experiment. J Dtsch Dermatol Ges. 2022;20(11):1441–1452. doi: 10.1111/ddg.14886.
   Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• Stalder JF, Barbarot S, Wollenberg A, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114–1121. doi: 10.1111/j.1398-9995.2011.02577.x.
   PubMed Web of Science ®Google Scholar
• Charman CR, Venn AJ, Ravenscroft JC, et al. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–1332. doi: 10.1111/bjd.12590.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502–507. doi: 10.2340/00015555-1246.
   PubMed Web of Science ®Google Scholar
• Verweyen E, Ständer S, Kreitz K, et al. Validation of a comprehensive set of pruritus assessment instruments: the chronic pruritus tools questionnaire PRURITOOLS. Acta Derm Venereol. 2019;99(7):657–663. doi: 10.2340/00015555-3158.
   PubMed Web of Science ®Google Scholar
• Narla S, Silverberg JI. Which clinical measurement tools for atopic dermatitis severity make the most sense in clinical practice? Dermatitis. 2023. Online ahead of print. doi: 10.1089/derm.2022.0087.
   Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
   PubMed Web of Science ®Google Scholar
• Newsom M, Bashyam AM, Balogh EA, et al. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020;80(11):1041–1052. doi: 10.1007/s40265-020-01335-7.
   PubMed Web of Science ®Google Scholar
• Nezamololama N, Fieldhouse K, Metzger K, et al. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;9:1–7. doi: 10.7573/dic.2020-8-5.
   Google Scholar
• Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):21–31. doi: 10.1016/j.anai.2020.08.016.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2018;121(4):464–468.e463. doi: 10.1016/j.anai.2018.07.004.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664. doi: 10.1111/j.0022-202X.2005.23621.x.
   PubMed Web of Science ®Google Scholar
• Boeri M, Sutphin J, Hauber B, et al. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatolog Treat. 2022;33(3):1449–1458. doi: 10.1080/09546634.2020.1832185.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Ho KA, Fifer S, et al. Patient and physician preferences for atopic dermatitis injection treatments in Japan. J Dermatolog Treat. 2020;31(8):821–830. doi: 10.1080/09546634.2019.1623860.
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Lio P, Weidinger S, et al. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatolog Treat. 2023;34(1):2222201.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815–824. doi: 10.1016/j.jaad.2022.07.019.
   PubMed Web of Science ®Google Scholar
• Wood H, Chandler A, Nezamololama N, et al. Safety of janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol. 2022;61(6):746–754. doi: 10.1111/ijd.15853.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Hong HC, Thyssen JP, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther. 2022;12(5):1181–1196. doi: 10.1007/s13555-022-00721-1.
   Web of Science ®Google Scholar
• Drucker AM, Lam M, Elsawi R, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023: ljad393. Online ahead of print. doi: 10.1093/bjd/ljad393.
   Google Scholar
• Silverberg JI, Armstrong A, Blauvelt A, et al. Assessment of efficacy and safety outcomes beyond week 16 in clinical ­trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids. Am J Clin Dermatol. 2023;24(6):913–925. doi: 10.1007/s40257-023-00809-0.
   PubMed Web of Science ®Google Scholar
• Duggan S. Tralokinumab: first approval. Drugs. 2021;81(14):1657–1663. doi: 10.1007/s40265-021-01583-1.
   PubMed Web of Science ®Google Scholar
• Bukhari RI, Alamr R, Alsindi RA, et al. Preferred mode of therapy among patients in rheumatoid arthritis saudi database: a cross-sectional study. Cureus. 2023;15(6):e41014. doi: 10.7759/cureus.41014.
   PubMed Web of Science ®Google Scholar
• Myers K, Silverberg JI, Parasuraman S, et al. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Treat. 2023;34(1):2215356.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285–1294. doi: 10.1001/archdermatol.2011.309.
   PubMedGoogle Scholar
• Daunt R, Curtin D, O’Mahony D. Polypharmacy stewardship: a novel approach to tackle a major public health crisis. Lancet Healthy Longev. 2023;4(5):e228–e235. doi: 10.1016/S2666-7568(23)00036-3.
   PubMedGoogle Scholar
• Werner RN, Ghoreschi K. Herpes zoster-prevention, diagnosis, and treatment. Hautarzt. 2022;73(6):442–451. doi: 10.1007/s00105-022-04992-9.
   PubMed Web of Science ®Google Scholar
• Ervin C, Crawford R, Evans E, et al. Patient and caregiver preferences on treatment attributes for atopic dermatitis. J Dermatolog Treat. 2022;33(4):2225–2233. doi: 10.1080/09546634.2021.1940810.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Wollenberg A, Eichenfield LF, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. Adv Ther. 2023;40(1):367–380. doi: 10.1007/s12325-022-02322-y.
   PubMed Web of Science ®Google Scholar